These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
499 related items for PubMed ID: 8445288
1. Human coagulation factor IX: assessment of thrombogenicity in animal models and viral safety. Herring SW, Abildgaard C, Shitanishi KT, Harrison J, Gendler S, Heldebrant CM. J Lab Clin Med; 1993 Mar; 121(3):394-405. PubMed ID: 8445288 [Abstract] [Full Text] [Related]
2. Inactivation and clearance of viruses during the manufacture of high purity factor IX. Johnston A, Macgregor A, Borovec S, Hattarki M, Stuckly K, Anderson D, Goss NH, Oates A, Uren E. Biologicals; 2000 Sep; 28(3):129-36. PubMed ID: 10964439 [Abstract] [Full Text] [Related]
3. A comparison of the in vitro and in vivo thrombogenic activity of factor IX concentrates using stasis (Wessler) and non-stasis rabbit models. Prowse CV, Williams AE. Thromb Haemost; 1980 Oct 31; 44(2):81-6. PubMed ID: 6779401 [Abstract] [Full Text] [Related]
11. Cutaneous and systemic effects of varying doses of brown recluse spider venom in a rabbit model. McGlasson DL, Harroff HH, Sutton J, Dick E, Elston DM. Clin Lab Sci; 2007 Oct 31; 20(2):99-105. PubMed ID: 17557708 [Abstract] [Full Text] [Related]
12. Biochemical and in vivo properties of high purity factor IX concentrates. Berntorp E, Björkman S, Carlsson M, Lethagen S, Nilsson IM. Thromb Haemost; 1993 Nov 15; 70(5):768-73. PubMed ID: 8128433 [Abstract] [Full Text] [Related]
14. Toxicity of factor IX concentrates in mice. Magner A, Aronson D. Dev Biol Stand; 1979 Nov 15; 44():185-8. PubMed ID: 544292 [Abstract] [Full Text] [Related]
15. Thrombogenicity of factor IX complex: in vivo investigation. Aronson DL, Menache D. Dev Biol Stand; 1987 Nov 15; 67():149-55. PubMed ID: 3609475 [Abstract] [Full Text] [Related]
16. Impact of infusion speed on the safety and effectiveness of prothrombin complex concentrate: a prospective clinical trial of emergency anticoagulation reversal. Pabinger I, Tiede A, Kalina U, Knaub S, Germann R, Ostermann H, Beriplex P/N Anticoagulation Reversal Study Group. Ann Hematol; 2010 Mar 15; 89(3):309-16. PubMed ID: 19787352 [Abstract] [Full Text] [Related]
17. The inhibitor of prothrombin conversion in plasma of patients on oral anticoagulant treatment. Bertina RM, Westhoek-Kuipers ME, Alderkamp GH. Thromb Haemost; 1981 Jun 30; 45(3):237-41. PubMed ID: 7281102 [Abstract] [Full Text] [Related]
18. Assessment of thrombogenicity of prothrombin complex concentrates in a porcine model. Harrison J, Abildgaard C, Lazerson J, Culbertson R, Anderson G. Thromb Res; 1985 Apr 15; 38(2):173-88. PubMed ID: 4002204 [Abstract] [Full Text] [Related]
19. Measurement of activated factor IX in factor IX concentrates: correlation with in vivo thrombogenicity. Gray E, Tubbs J, Thomas S, Oates A, Boisclair M, Kemball-Cook G, Barrowcliffe TW. Thromb Haemost; 1995 Apr 15; 73(4):675-9. PubMed ID: 7495077 [Abstract] [Full Text] [Related]